NDA Group is a world leading regulatory and drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board. Our goal is to streamline drug development in order to accelerate patient access to important medical therapies.

About NDA

Services

Translational Science

NDA Advisory Board

Regulatory Affairs

Pharmaco-
vigilance

High-Stakes Meetings

Medical Devices

News

Kurt Stoeckli joins NDA as President NDA Advisory Services

2nd April 2020

We are happy to announce and welcome Kurt Stoeckli to the team as President NDA Advisory Board.

More

Webinar – Opportunities to Enhance Pharmacovigilance in Oncology

31st March 2020

On Thursday 23 April 2020, 15:00 BST, 16:00 CEST & 10:00 EDT,  Dr Brian Edwards Principal Consultant, Pharmacovigilance & Drug Safety, NDA Group, will discuss current best practices and opportunities for future improvement in oncology safety processes.

More

NDA Medical Device Division launched

19th March 2020

We are proud to announce the creation of a new division within NDA, focusing on advice and support to companies facing increasing regulatory challenges in the device space.

More

ATMP and Market Access seminar in Sweden – Postponed

27th February 2020

As a result of the increased spread of the Corona virus and due to the Public Health Agency’s now changed assessment of the risk level for the spread of the virus – an increase in risk level to “Very High risk” we have decided to postpone our planned seminar.

More

We would like to meet you at the DIA 2020

20th February 2020

Are you and/or your team attending the DIA next month?  Stop by our booth, D5, and talk to one of our team about how we can support you to optimise your path to approval.

More

Hopes and challenges in the future of the immuno-oncology field

31st January 2020

There is no doubt that the area of oncology development has exploded in the last few years.

More

Celebrating the work of a patient advocate

28th January 2020

Throughout his career Markku Toivonen has been a staunch patient advocate, focusing his life’s work on ensuring that suitable medicines accelerate and that only those products reach physicians and patients.

More
More News
We have helped over 2,000 clients achieve success in the past
We have helped over 2,000 clients achieve success in the past

The leader in FDA Advisory Committee meeting preparation

“For innovative life science companies, NDA and PharmApprove are the best partners to help prepare to win at FDA Advisory Committees. Our pioneering approach — refined over 16 years experience and 150-plus projects — has helped more than 80 clients achieve success at these high-profile, high-stakes hearings.

NDA Intelligence

Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.

Members

A Career with NDA

Join NDA and get the chance to work with some of the leading minds in regulatory affairs, pharmacovigilance, health technology assessment and scientific communications on a variety of projects, clients and geographies.

Why work at NDA?

Our Locations

NDA Sweden

NDA Group AB
Johanneslundsv. 2
S-194 61 Upplands Väsby
Sweden

T. +46 (0)8 590 778 00
E. stockholm@ndareg.com

NDA France

7, rue Jobbé Duval,
75015 Paris,
France

T. +33 983 981 942
E. paris@ndareg.com

NDA Germany

Neumarkter Straße 18
D-81673 München
Germany

T. +49 (0)89 3585 4000
E. munich@ndareg.com

NDA Switzerland

Rigistrasse 5
8703 Erlenbach
Switzerland

T. +41 (0)78 951 9929
E. zurich@ndareg.com

NDA UK

Grove House
Guildford Road
Leatherhead,
Surrey KT22 9DF
United Kingdom

T. +44 (0) 1372 860 610
E. london@ndareg.com

NDA USA Massachusetts

NDA Regulatory Development Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
United States

T. +1 609 583 1990
E. usa@ndareg.com

NDA USA New Jersey

PharmApprove
200 Princeton South Corporate Center,
Suite 340
Ewing, NJ 08628
United States

T. +1 609 583 1990
E. usa@ndareg.com